Mineralys Raises $150 Million via 5.66M Share Offering at $26.50
MLYS•Mineralys Therapeutics priced an underwritten offering of 5,660,378 common shares at $26.50 each, raising gross proceeds of approximately $150 million. Net proceeds will fund part of a $200 million upfront payment to repurchase royalty obligations under its Tanabe Pharma license agreement.
1. Offering Terms
Mineralys Therapeutics is selling 5,660,378 common shares at $26.50 per share in an underwritten offering, generating gross proceeds of approximately $150 million before fees. The offering is supported by joint book-runners BofA Securities, Goldman Sachs and Evercore ISI and is expected to close on or about June 4, 2026, subject to customary conditions.
2. Use of Proceeds
Proceeds from the equity offering will fund a portion of the $200 million upfront payment to repurchase the royalty obligation under the license agreement with Tanabe Pharma Corporation. This strategic move reduces future royalty burdens and strengthens control over lorundrostat rights.
3. Debt Facility
Earlier on the same day, Mineralys secured a committed $500 million debt facility with funds managed by Pharmakon Advisors, LP. The combination of equity and debt financing positions the company to advance its pipeline while optimizing its capital structure.
4. Financial Impact
The equity offering and debt facility will increase Mineralys’ liquidity for ongoing development of its aldosterone synthase inhibitor program but will also introduce share dilution and higher leverage. Investors should monitor the closing conditions and the impact on future earnings per share.
